Exploration of molecular prognostic factors related to genotype and immunomodulation in localised GIST. (Q3144263): Difference between revisions
Jump to navigation
Jump to search
(Created claim: summary (P836): Gastrointestinal stromal tumors (GIST) are the most common sarcomas. Our group demonstrated the relevance of the genotype in recurrence-free survival in patients with localised GIST. In particular, patients with mutations affecting codons 557/558 of exon 11 of the KIT gene have a significant and independent risk of recurrence. However, molecular factors that explain the increased risk of recurrence in carriers of critical mutations have not been...) |
(Changed label, description and/or aliases in en: translated_label) |
||
| label / en | label / en | ||
Exploration of molecular prognostic factors related to genotype and immunomodulation in localised GIST. | |||
Revision as of 14:01, 12 October 2021
Project Q3144263 in Spain
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Exploration of molecular prognostic factors related to genotype and immunomodulation in localised GIST. |
Project Q3144263 in Spain |
Statements
41,200.0 Euro
0 references
51,500.0 Euro
0 references
80.0 percent
0 references
1 January 2016
0 references
16 December 2018
0 references
FUNDACION PUBLICA ANDALUZA PARA LA GESTION DE LA INVESTIGACION EN SALUD DE SEVILLA
0 references
37°23'19.07"N, 5°59'43.22"W
0 references
41091
0 references
Los tumores de estroma gastrointestinal (GIST) son los sarcomas más frecuentes. Nuestro grupo demostró la relevancia del genotipo en la supervivencia libre de recidiva en pacientes con GIST localizados. Concretamente, pacientes portadores de mutaciones que afecten a codones 557/558 del exón 11 del gen KIT, presentan un significativo e independiente mayor riesgo de recidiva. Sin embargo no se ha encontrado hasta el momento los factores moleculares que expliquen el mayor riesgo de recidiva en los portadores de las mutaciones críticas. En este estudio proponemos, en primer lugar, un análisis trascriptómico comparativo de portadores de mutaciones críticas respecto a otros genotipos. La hipótesis es que los portadores de mutaciones críticas presenten una expresión génica diferente de forma que planteara potenciales nuevas dianas terapéuticas. Por otra parte, planteamos un análisis de biomarcadores de inmunomodulación, mediante expresión proteínica, en la misma población de GIST localizados. La hipótesis es que la expresión de ciertos marcadores inmunológicos tendrían relevancia pronóstica en GIST localizados. Además, será de elevado interés correlacionar si los distintos genotipos no sólo tienen impacto en distintas señalizaciones génicas sino también en distinta expresión de marcadores inmunológicos. Para realizar los estudios previstos, contamos con el registro GIST del grupo GEIS con información clínico, patológica y molecular de alrededor de 400 pacientes con diagnóstico de GIST sin tratamiento adyuvante. Adicionalmente, los hospitales participantes en este proyecto multicéntrico aportarán nuevos casos de pacientes con GIST localizados tratados con Imatinib adyuvante. (Spanish)
0 references
Gastrointestinal stromal tumors (GIST) are the most common sarcomas. Our group demonstrated the relevance of the genotype in recurrence-free survival in patients with localised GIST. In particular, patients with mutations affecting codons 557/558 of exon 11 of the KIT gene have a significant and independent risk of recurrence. However, molecular factors that explain the increased risk of recurrence in carriers of critical mutations have not been found so far. In this study, we propose, first, a comparative transcryptomic analysis of carriers of critical mutations compared to other genotypes. The hypothesis is that carriers of critical mutations present a different gene expression in such a way as to pose potential new therapeutic targets. On the other hand, we propose an analysis of immunomodulation biomarkers, using protein expression, in the same population of localised GIST. The hypothesis is that the expression of certain immunological markers would have prognostic relevance in localised GIST. In addition, it will be of great interest to correlate if the different genotypes have an impact not only on different gene signs but also on different expressions of immunological markers. To carry out the planned studies, we have the GIST registry of the GEIS group with clinical, pathological and molecular information from around 400 patients diagnosed with GIST without adjuvant treatment. In addition, the hospitals participating in this multicenter project will provide new cases of patients with localised GIST treated with adjuvant Imatinib. (English)
12 October 2021
0 references
Sevilla
0 references
Identifiers
PI15_01254
0 references